Sweeney & Michel’s CRISPR Therapeutics CRSP Stock Holding History

Sweeney & Michel’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,944	Closed	-$215K	–	144
2025 Q3	$215K	Buy	+2,944	New	+$169K	0.07%	130

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sweeney & Michel's CRSP Position: Q4 2025 in Review

Sweeney & Michel sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 2,944 shares — an estimated $215K sold.

Sweeney & Michel first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $215K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Sweeney & Michel reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Sweeney & Michel sold 2,944 CRISPR Therapeutics shares in Q4 2025, an estimated $215K.
Sweeney & Michel first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
Sweeney & Michel's CRISPR Therapeutics position peaked at $215K in Q3 2025.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Sweeney & Michel's 13F filing for Q4 2025, filed 13 Feb 2026.